Clinical Trial

Bleeding Prevention With Desmopressin for Allograft Kidney Biopsies

Study acronym: BRIDGE
Enrolling by Invitation Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated September 11, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this study is to evaluate the efficacy and safety of desmopressin to prevent bleeding after percutaneous renal graft biopsy in patients at high risk of bleeding. Researchers will compare desmopressin (DDAVP) to placebo to see if the drug reduces the risk of bleeding events related to kidney biopsy. Participants will receive intravenous desmopressin medication (100ml) or placebo (100mL of saline solution) before the kidney biopsy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-09-30; most recent amendment 2025-09-05.
Trial Details
NCT Number NCT06622187
Lead Sponsor Hospital de Clinicas de Porto Alegre
Conditions Bleeding, Transplant, Kidney, Desmopressin, Kidney Biopsy
Enrollment 96 participants
Start Date 2024-08-14
Primary Completion 2026-06 (estimated)
Study Completion 2026-06-14 (estimated)
Updated on ClinicalTrials.gov 2025-09-11